Health and Healthcare

Amgen : AMGN

All Amgen Articles

720 Articles

Jon C. Ogg | May 23, 2019 at 11:40 AM EDT

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and…

Jon C. Ogg | May 23, 2019 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia,…

Chris Lange | May 21, 2019 at 9:05 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors…

Chris Lange | May 10, 2019 at 8:55 AM EDT

Short Sellers Back Off Major Biotechs

The April 30 short interest data have been compared with the previous report, and short interest in most of these…

Chris Lange | Apr 26, 2019 at 9:40 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest moves in these selected…

Jon C. Ogg | Apr 24, 2019 at 12:55 PM EDT

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

Lee Jackson | Apr 23, 2019 at 7:40 AM EDT

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value…

Chris Lange | Apr 10, 2019 at 9:15 AM EDT

Big Biotechs Confound Short Sellers

The March 29 short interest data have been compared with the previous report, and short interest moves in these selected…

Chris Lange | Mar 27, 2019 at 8:30 AM EDT

Big Biotechs Scare Off Short Sellers

The March 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 12, 2019 at 9:05 AM EDT

Major Biotechs See a Rising Tide in Short Interest

The February 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Feb 28, 2019 at 8:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data…

Trey Thoelcke | Feb 22, 2019 at 8:00 AM EST

Johnson & Johnson and Other Health Care Stocks With Recent Death Crosses

Here are five top health care stocks that recently saw their 50-day moving average cross below the 200-day average, a…

Chris Lange | Feb 12, 2019 at 9:55 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data…

Jon C. Ogg | Jan 29, 2019 at 3:01 PM EST

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower…

Chris Lange | Jan 28, 2019 at 8:30 AM EST

Short Sellers Back Off Major Biotechs

The January 15 short interest data have been compared with the previous report, and short interest in most of the…

1 … 14 15 16 17 18 … 48

Amgen : AMGN

All Amgen Articles

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Big Biotechs Confound Short Sellers

Big Biotechs Scare Off Short Sellers

Major Biotechs See a Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Johnson & Johnson and Other Health Care Stocks With Recent Death Crosses

Short Sellers Run for Cover From Major Biotechs

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

Short Sellers Back Off Major Biotechs

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Amgen : AMGN

All Amgen Articles

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Big Biotechs Confound Short Sellers

Big Biotechs Scare Off Short Sellers

Major Biotechs See a Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Johnson & Johnson and Other Health Care Stocks With Recent Death Crosses

Short Sellers Run for Cover From Major Biotechs

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

Short Sellers Back Off Major Biotechs

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Featured Reads

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.